Estimating the cost of illness
In: Public Health Service publication 947-6
In: Health economics series 6
158677 Ergebnisse
Sortierung:
In: Public Health Service publication 947-6
In: Health economics series 6
SSRN
Working paper
In: Society and economy: journal of the Corvinus University of Budapest, Band 37, Heft 4, S. 531-542
ISSN: 1588-970X
The paper provides a systematic review on the cost-of-illness studies in an age-associated condition with high prevalence, benign prostatic hyperplasia (BPH), published in Medline between 2005 and 2015. Overall 11 studies were included, which were conducted in 8 countries. In the US, the annual direct medical costs per patient ranged from $255 to $5,729, while in Europe from €253 to €1,251. In 2008, in the UK total annual direct medical costs of BPH were £180.8 million at national level. In the US, overall costs of BPH management in the private sector were estimated at $3.9 billion annually, of which $500 million was attributable to productivity loss (year 1999). Due to demographic factors and possible surgical innovations in the field of urology, the costs of BPH are likely to increase in the future. Over the next decade the age of retirement is projected to rise, consequently, the indirect costs related to aging-associated conditions such as BPH are expected to soar. To promote the transparent and cost-effective management of BPH, development of rational clinical guidelines would be essential that may lead to significant improvement in quality of care as well as reduction in healthcare expenditure.
In: http://www.biomedcentral.com/1756-0500/8/539
Abstract Background Breast cancer is a major cause of death for women in Japan. The objectives of this study were to estimate and project the economic burden associated with breast cancer in Japan and identify the key factors that drive the change of the economic burden of breast cancer. Methods We calculated the cost of illness (COI) every 3 years from 1996 to 2020 using governmental statistics. COI was calculated by summing the direct costs, morbidity costs, and mortality costs. Results From 1996 to 2011 COI was trending upward. COI in 2011 (697 billion yen) was 1.7-times greater than that in 1996 (407 billion yen). The mortality costs accounted for approximately 65–70 % of the total COI and were a major contributing factor to increase in COI. It was predicted that COI would continue to trend upwards until 2020 (699.4–743.8 billion yen depending on the model), but the rate of increase would decline. Conclusions COI of breast cancer has been steadily increasing since 1996. While the rate of increase is expected to plateau, the average age at death from breast cancer is still less than that from other cancers, and the relative economic burden of breast cancer will continue to increase in the foreseeable future.
BASE
How to finance and provide health care for the more than 1.3 billion rural poor and informal sector workers in low- and middle-income countries is one of the greatest challenges facing the international development community. This article presents the main findings from an extensive survey of the literature of community financing arrangements, and selected experiences from the Asia and Africa regions. Most community financing schemes have evolved in the context of severe economic constraints, political instability, and lack of good governance. Micro-level household data analysis indicates that community financing improves access by rural and informal sector workers to needed heath care and provides them with some financial protection against the cost of illness. Macro-level cross-country analysis gives empirical support to the hypothesis that risk-sharing in health financing matters in terms of its impact on both the level and distribution of health, financial fairness and responsiveness indicators. The background research done for this article points to five key policies available to governments to improve the effectiveness and sustainability of existing community financing schemes. This includes: (a) increased and well-targeted subsidies to pay for the premiums of low-income populations; (b) insurance to protect against expenditure fluctuations and re-insurance to enlarge the effective size of small risk pools; (c) effective prevention and case management techniques to limit expenditure fluctuations; (d) technical support to strengthen the management capacity of local schemes; and (e) establishment and strengthening of links with the formal financing and provider networks.
BASE
Abstract: The increase in the number of chronic kidney disease (CKD) sufferers and the expensive financing of this disease, the economic burden borne will certainly increase. This study aimed to determine the cost of illness of CKD patients undergoing hemodialysis, as well as to find out the comparison of real costs with INA-CBG's rates. This was a pharmacoeconomic research, used the cost of illness method according to a societal perspective. The study was conducted in a type B government hospitals in Yogyakarta from January to March 2020. The population in this study were all CKD patients undergoing hemodialysis in need to mention the hospital at first. The research instruments were medical records, hospital financial data, and patient interviews. The complete data were analyzed statistically with the descriptive method and the Mann Whitney test. The number of samples was 65 patients. The results revealed the average cost of illness was 6,224,277.00 IDR for one month of treatment. The cost component that dominates was hemodialysis rate. The average real cost was 836,686 IDR for one procedure. It can be concluded that the average real cost of CKD patients with hemodialysis in the type B government hospital were significantly smaller than the INA-CBG's rate.Keywords: Chronic Kidney Disease; Hemodialysis; Cost Of Illness; INA-CBG's Rate
BASE
BACKGROUND: Cost-of-illness data from empirical studies provide insights into the use of healthcare resources including both expenditures and the opportunity cost related to receiving treatment. OBJECTIVE: The objective of this systematic review was to gather cost data and relevant parameters for hepatitis B, pneumonia, meningitis, encephalitis caused by Japanese encephalitis, rubella, yellow fever, measles, influenza, and acute gastroenteritis in children in low- and middle-income countries. DATA SOURCES: Peer-reviewed studies published in public health, medical, and economic journals indexed in PubMed (MEDLINE), Embase, and EconLit. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: Studies must (1) be peer reviewed, (2) be published in 2000–2016, (3) provide cost data for one of the nine diseases in children aged under 5 years in low- and middle-income countries, and (4) generated from primary data collection. LIMITATIONS: We cannot exclude missing a few articles in our review. Measures were taken to reduce this risk. Several articles published since 2016 are omitted from the systematic review results, these articles are included in the discussion. CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: The review yielded 37 articles and 267 sets of cost estimates. We found no cost-of-illness studies with cost estimates for hepatitis B, measles, rubella, or yellow fever from primary data. Most estimates were from countries in Gavi preparatory (28%) and accelerated (28%) transition, followed by those who are initiating self-financing (22%) and those not eligible for Gavi support (19%). Thirteen articles compared household expenses to manage illnesses with income and two articles with other household expenses, such as food, clothing, and rent. An episode of illness represented 1–75% of the household's monthly income or 10–83% of its monthly expenses. Articles that presented both household and government perspectives showed that most often governments incurred greater costs than households, including non-medical ...
BASE
In: http://www.biomedcentral.com/1472-6963/13/283
Abstract Background Stomach cancer is one of the leading causes of cancer deaths in Japan. The objectives of this study were to estimate and project the economic burden associated with stomach cancer in Japan, and to identify the key factors that drive the economic burden of stomach cancer. Methods We calculated Cost of illness (COI) of 1996, 2002, 2008, 2014 and 2020 by using government office statistics and the COI method. We calculated direct cost and indirect cost (morbidity cost and mortality cost), and estimated the COI by summing them up. Results The number of deaths remained at approximately 50,000 in 1996–2008. COI was in downward trend from 1,293.5 billion yen in 1996 to 1,114.2 billion yen in 2008. Morbidity cost was 85.6 billion yen and 54.0 billion yen, mortality cost was 972.3 billion yen and 806.4 billion yen, and mortality cost per person was 19.4 million yen and 16.1 million yen in 1996 and 2008, respectively. Decrease of mortality cost that accounted for a large part of the COI (72.4% in 2008) was the major contributing factor. COI is predicted to decrease if the trend of health related indicators continues (442.8-1,056.1 billion yen depending on the model in 2020). Mortality cost per person is also predicted to decrease (9.5-12.5 million yen depending on the model in 2020). Conclusions If the trend of health related indicators continues, it is estimated that COI of stomach cancer would decrease. "Aging", "change of the healthcare providing system" and "new medical technology" are considered as contributing factors of COI.
BASE
In: Alcohol and alcoholism: the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA), Band 47, Heft 6, S. 725-731
ISSN: 1464-3502
In: Central European journal of public policy: CEJPP, Band 14, Heft 1, S. 43-56
ISSN: 1802-4866
Abstract
The article addresses the need to identify and quantify the external costs of air pollution on the health of the population, especially children. The subjects of evaluation are the respiratory illnesses acute nasopharyngitis and acute bronchitis, both of which have very high incidence in connection with air pollution. The aim of this paper is to estimate the cost of morbidity and to determine the amount of additional social costs of airway morbidity among children aged 0–15 years in Ostrava city, one of the most polluted cities in Europe, compared to the incidence of these diseases in the whole Czech Republic. Estimation of social costs is based on the Cost-Of-Illness approach, in which the total value is made up of the costs actually incurred in treating illness and in loss of productivity. Using this approach, additional costs related to the treatment of illnesses were calculated at approximately €20 million per year, which represents approximately 0.4% of Ostrava's regional gross domestic product (GDP).